Clinical trials: Doxorubicin
Recurrent Uterine Corpus Carcinoma, Stage IIIA Uterine Corpus Cancer AJCC v7
Doxorubicin Hydrochloride, Cisplatin, and Paclitaxel or Carboplatin and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer
This randomized phase III trial compares how well two different combination chemotherapy regimens (doxorubicin hydrochloride, cisplatin, and paclitaxel versus carboplatin and paclitaxel) work in treating patients with endometrial…
- Conditions
- Recurrent Uterine Corpus Carcinoma, Stage IIIA Uterine Corpus Cancer AJCC v7, Stage IIIB Uterine Corpus Cancer AJCC v7, Stage IIIC Uterine Corpus Cancer AJCC v7
- Trial name
- NCT00063999
- Testing
- Carboplatin, Cisplatin, Doxorubicin Hydrochloride
- Where
- 650 sites in United States, Canada and 1 more
- Volunteers
- 1,381 people
- Sponsor
- GOG Foundation
Cardiotoxicity, Risk Factor, Cardiovascular
Risk-Guided Cardioprotection With Carvedilol in Breast Cancer Patients Treated With Doxorubicin and/or Trastuzumab
Investigators will evaluate the safety, tolerability, and feasibility of a risk-guided cardioprotective treatment strategy with carvedilol, as compared to usual care, in breast cancer patients undergoing treatment with…
- Conditions
- Cardiotoxicity, Risk Factor, Cardiovascular, Toxicity Due to Chemotherapy, Breast Cancer
- Trial name
- CCTGuide Pilot (NCT04023110)
- Testing
- Carvedilol
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
High-grade Serous Ovarian Cancer
p53 Activation in Platinum-Resistant High Grade Serous Ovarian Cancer, a Study of PLD With APR-246
The purpose of this study is to make a preliminary assessment of the efficacy of a combined APR-246 and PLD chemotherapy regimen in patients with platinum-resistant recurrent high grade serous ovarian cancer (HGSOC) with mutated…
- Trial name
- NCT03268382
- Testing
- APR-246, Pegylated Liposomal Doxorubicin Hydrochloride (PLD)
- Where
- 12 sites in Belgium, Spain and 1 more
- Volunteers
- 36 people
- Sponsor
- Aprea Therapeutics
Ovarian Cancer
Caelyx Biweekly in Heavily Pretreated Patients With Relapsed Ovarian Cancer
Effect of biweekly schedule of PLD on dose-limiting toxicity of PPE and patient's quality of life
- Trial name
- NCT00170573
- Testing
- Caelyx
- Volunteers
- 77 people
- Sponsor
- North Eastern German Society of Gynaecological Oncology
Triple-negative Breast Cancer
Neoadjuvant Study of Two Platinum Regimens in Triple Negative Breast Cancer
Evaluate if the two carboplatin containing chemotherapy regimens will reduce the growth of breast cancer cells in women with Stage I, II, or III triple negative breast cancer.
- Trial name
- NeoSTOP (NCT02413320)
- Testing
- Paclitaxel, Carboplatin, Doxorubicin
- Where
- 9 sites in United States
- Volunteers
- 101 people
- Sponsor
- Priyanka Sharma
Basal Cell Carcinoma
Dose Escalation Trial to Evaluate Dose Limiting Toxicity/Maximum Tolerated Dose of Microneedle Arrays Containing Doxorubicin (D-MNA) in Basal Cell Carcinoma (BCC)
This is a Phase I study in participants with superficial or nodular Basal Cell Carcinoma (BCC), designed to assess dose limiting toxicities and maximum tolerated dose, efficacy, safety, and tolerability of dissolvable…
- Trial name
- NCT03646188
- Testing
- 25 µg doxorubicin-containing MNA, 50 µg doxorubicin-containing MNA, 100 µg doxorubicin-containing MNA
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- SkinJect, Inc.
Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma
Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
This phase II trial studies how well etoposide, prednisone, vincristine sulfate, cyclophosphamide, and doxorubicin (DA-EPOCH) works in treating patients with acute lymphoblastic leukemia or lymphoblastic lymphoma.
- Trial name
- NCT03023046
- Testing
- Cyclophosphamide, Dasatinib, Doxorubicin
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- University of Washington
Platinum-resistant Ovarian Cancer, Fallopian Tube Cancer
Phase 1b Study of SL-172154 Administered With Combination Agent(s) in Subjects With Ovarian Cancers
SL03-OHD-105 is an open-label, multicenter, phase 1b trial designed to evaluate SL-172154 administered in combination with pegylated liposomal doxorubicin (PLD) or mirvetuximab soravtansine (MIRV) in patients with platinum…
- Conditions
- Platinum-resistant Ovarian Cancer, Fallopian Tube Cancer, Epithelial Ovarian Cancer, Ovarian Cancer
- Trial name
- NCT05483933
- Testing
- Pegylated Liposomal Doxorubicin + SL-172154, Mirvetuximab + SL-172154
- Where
- 21 sites in United States, Canada and 2 more
- Volunteers
- 86 people
- Sponsor
- Shattuck Labs, Inc.
Chemotherapy-induced Neutropenia
Dose-finding Study of Empegfilgrastim for Neutropenia Prophylaxis in Patients With Breast Cancer
The purpose of the study is to compare safety and efficacy of a single dose of empegfilgrastimt a dose of 3 or 6 mg versus daily administration of filgrastim at a dose of 5 μg/kg/day.
- Trial name
- NCT01569087
- Testing
- empegfilrastim, filgrastim
- Where
- 5 sites in Russia
- Volunteers
- 60 people
- Sponsor
- Biocad
Lymphoma
Stage I/II Nasal NK Cell Lymphoma
The goal of this clinical research study is to learn if radiation therapy and chemotherapy can help control stage 1 and/or 2 NK cell lymphoma. The safety of radiation and chemotherapy will also be studied.
- Trial name
- NCT01321008
- Testing
- Radiation, Cyclophosphamide, Doxorubicin
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- M.D. Anderson Cancer Center
Breast Cancer
Doxorubicin and Cyclophosphamide Followed by Paclitaxel, Trastuzumab, and Lapatinib in Treating Patients With HER2/Neu-Overexpressed Breast Cancer
The purpose of this study is to study a new treatment for HER-2/neu (+) breast cancer.
- Trial name
- NCT00482391
- Testing
- trastuzumab, cyclophosphamide, doxorubicin hydrochloride
- Where
- 2 sites in United States
- Volunteers
- 95 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Soft Tissue Sarcoma, Adult, Soft Tissue Sarcoma, Child
Safety, Tolerability, and Efficacy of Doxorubicin and Pembrolizumab for Sarcoma
The purpose of this study is to evaluate the safety, tolerability and efficacy of doxorubicin in combination with pembrolizumab in subjects with metastatic or unresectable soft tissue sarcoma.
- Trial name
- NCT03056001
- Testing
- Pembrolizumab, Doxorubicin
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Wake Forest University Health Sciences
Breast Cancer, Metastatic Breast Cancer
Phase 2 Neoadjuvant Doxorubicin and Cyclophosphamide -> Docetaxel With Lapatinib in Stage II/III Her2Neu+ Breast Cancer
This trial combines dose dense chemotherapy with doxorubicin and cyclophosphamide (AC) followed by standard, every 3 week docetaxel and GW572016 (lapatinib) for neoadjuvant treatment of Her2neu positive stage II/III breast…
- Trial name
- NCT00404066
- Testing
- Lapatinib, Doxorubicin, Cyclophosphamide
- Where
- 2 sites in United States
- Volunteers
- 21 people
- Sponsor
- George Albert Fisher
Ovarian Neoplasms, Breast Neoplasms
A Study to Determine the Management of Palmar-plantar Erythrodysesthesia (PPE) in Patients With Metastatic Ovarian or Breast Cancer Treated With Caelyx (Study P05020)
The objective of this trial is to study the management of PPE in participants with metastatic ovarian or breast cancer treated with Caelyx, and determine the frequency of use of pharmacological treatment (preventive or…
- Conditions
- Ovarian Neoplasms, Breast Neoplasms, Paresthesia
- Trial name
- NCT00746694
- Volunteers
- 154 people
- Sponsor
- Merck Sharp & Dohme LLC
Diffuse, Large B-Cell, Lymphoma, Follicular Lymphoma, Grade 3b
Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular Lymphoma
This is a Phase 2 study to evaluate the combination of denintuzumab mafodotin in combination with RCHOP or RCHP compared with RCHOP alone as front-line therapy in patients with diffuse large B-cell lymphoma or follicular lymphoma…
- Conditions
- Diffuse, Large B-Cell, Lymphoma, Follicular Lymphoma, Grade 3b, Transformed Lymphoma / DLBCL
- Trial name
- NCT02855359
- Testing
- denintuzumab mafodotin, rituximab, cyclophosphamide
- Where
- 35 sites in United States, Puerto Rico
- Volunteers
- 24 people
- Sponsor
- Seagen Inc.
Leiomyosarcoma, Uterine Neoplasm
Adjuvant Chemotherapy for High Risk Uterine Leiomyosarcoma
The purpose of this trial is to study the benefits of giving chemotherapy to women after they have had surgical resection of their primary disease and have no evidence of disease remaining(known as adjuvant therapy).
- Trial name
- NCT00282087
- Testing
- gemcitabine, docetaxel, doxorubicin
- Where
- 12 sites in United States
- Volunteers
- 47 people
- Sponsor
- Sarcoma Alliance for Research through Collaboration
Multiple Myeloma
Carfilzomib, Pegylated Liposomal Doxorubicin Hydrochloride, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
The aim of this phase I/II trial is to determine the maximal tolerated dose (MTD) of carfilzomib together with pegylated liposomal doxorubicin hydrochloride (PLD) with or without dexamethasone, and then to establish the efficacy…
- Trial name
- NCT01246063
- Testing
- carfilzomib, pegylated liposomal doxorubicin (PLD), Dexamethasone
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Washington University School of Medicine
Multiple Myeloma
A Study of Efficacy of Treatment With Bortezomib (in Combination With Doxorubicin and Dexamethasone) in Previously Untreated Patients With Multiple Myeloma
The purpose of this study is to determine efficacy of treatment with bortezomib (in combination with doxorubicin and dexamethasone) in previously untreated patients with Multiple Myeloma.
- Trial name
- NCT00872521
- Testing
- PAD induction
- Where
- 16 sites in Australia
- Volunteers
- 107 people
- Sponsor
- Janssen-Cilag Pty Ltd
Lymphoma, Mantle-Cell
Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody Plus CHOP For Untreated Mantle Cell Lymphoma
The primary efficacy endpoint of this study is to determine the duration of response of the sequential administration of Iodine-131 Anti-B1 Antibody followed by six cycles of CHOP for patients with previously untreated Mantle…
- Trial name
- NCT00992992
- Testing
- Tositumomab and Iodine I 131 Tositumomab followed by CHOP
- Volunteers
- 25 people
- Sponsor
- GlaxoSmithKline
Breast Cancer
Docetaxel in Breast Cancer
Primary objective : To compare disease-free survival after treatment with docetaxel in combination with doxorubicin and cyclophosphamide to doxorubicin and cyclophosphamide followed by docetaxel in operable adjuvant breast cancer…
- Trial name
- NCT00312208
- Testing
- docetaxel, doxorubicin, cyclophosphamide, Docetaxel,doxorubicin, cyclophosphamide
- Where
- 37 sites in United States, Argentina and 35 more
- Volunteers
- 3,299 people
- Sponsor
- Sanofi